Literature DB >> 27707475

Patient need versus evidence: a balancing act.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27707475     DOI: 10.1016/S0140-6736(16)31765-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Nhu Trieu; Bo Bao; Bailey Miskew Nichols; Maria Candida Vila; James S Novak; Yuko Hara; Joshua Lee; Aleksander Touznik; Kamel Mamchaoui; Yoshitsugu Aoki; Shin'ichi Takeda; Kanneboyina Nagaraju; Vincent Mouly; Rika Maruyama; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2017-07-28       Impact factor: 11.454

Review 2.  Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.

Authors:  Quynh Nguyen; Toshifumi Yokota
Journal:  J Pers Med       Date:  2017-10-16

Review 3.  Exon-Skipping in Duchenne Muscular Dystrophy.

Authors:  Shin'ichi Takeda; Paula R Clemens; Eric P Hoffman
Journal:  J Neuromuscul Dis       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.